Amedisys Inc (AMED) Shares Bought by 361 Capital LLC

361 Capital LLC increased its holdings in Amedisys Inc (NASDAQ:AMED) by 9.4% in the first quarter, HoldingsChannel.com reports. The fund owned 22,767 shares of the health services provider’s stock after acquiring an additional 1,957 shares during the period. 361 Capital LLC’s holdings in Amedisys were worth $2,806,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. ETF Managers Group LLC purchased a new position in shares of Amedisys in the 1st quarter worth about $511,000. Oregon Public Employees Retirement Fund raised its position in shares of Amedisys by 86.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,611 shares of the health services provider’s stock worth $2,541,000 after purchasing an additional 9,575 shares during the last quarter. Mid Atlantic Financial Management Inc. ADV purchased a new position in shares of Amedisys in the 1st quarter worth about $272,000. Mason Street Advisors LLC raised its position in shares of Amedisys by 71.9% in the 1st quarter. Mason Street Advisors LLC now owns 15,490 shares of the health services provider’s stock worth $1,909,000 after purchasing an additional 6,478 shares during the last quarter. Finally, Raymond James & Associates raised its position in shares of Amedisys by 8.3% in the 1st quarter. Raymond James & Associates now owns 7,778 shares of the health services provider’s stock worth $959,000 after purchasing an additional 596 shares during the last quarter. 91.71% of the stock is owned by institutional investors.

Several research firms have recently issued reports on AMED. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 14th. Benchmark lowered Amedisys from a “buy” rating to a “hold” rating and set a $136.64 price target for the company. in a research report on Tuesday, February 5th. ValuEngine raised Amedisys from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $151.00 price target for the company in a research report on Thursday, February 7th. Finally, Barclays lifted their price target on Amedisys from $115.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company’s stock. Amedisys currently has an average rating of “Hold” and a consensus price target of $125.90.

In other news, Director Bruce D. Perkins purchased 2,500 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was acquired at an average cost of $111.84 per share, for a total transaction of $279,600.00. Following the purchase, the director now directly owns 22,088 shares in the company, valued at approximately $2,470,321.92. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David L. Kemmerly sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $118.20, for a total value of $591,000.00. The disclosure for this sale can be found here. Insiders sold a total of 18,281 shares of company stock valued at $2,160,243 over the last quarter. 2.90% of the stock is owned by corporate insiders.

NASDAQ AMED opened at $108.34 on Monday. Amedisys Inc has a one year low of $71.74 and a one year high of $140.91. The stock has a market capitalization of $3.47 billion, a P/E ratio of 29.85, a price-to-earnings-growth ratio of 1.35 and a beta of 1.33. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, April 30th. The health services provider reported $1.11 EPS for the quarter, topping the consensus estimate of $0.89 by $0.22. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The company had revenue of $467.34 million during the quarter, compared to the consensus estimate of $460.83 million. During the same period last year, the company earned $0.79 EPS. Amedisys’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, sell-side analysts expect that Amedisys Inc will post 4.08 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Amedisys Inc (AMED) Shares Bought by 361 Capital LLC” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/20/amedisys-inc-amed-shares-bought-by-361-capital-llc.html.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.